Elanco Announces R&D Collaboration with AgBiome

( MGN )

Elanco Animal Health Incorporated announced on Thursday a new global R&D collaboration with AgBiome, Inc. to develop nutritional health products for swine.

According to a company release, the collaboration demonstrates Elanco’s deep commitment to antibiotic stewardship and bringing alternatives to producers’ most difficult challenges.

The research and development collaboration with AgBiome plans to deliver probiotic solutions to some of swine producers’ greatest gut health challenges. Elanco will be able to leverage AgBiome’s proprietary strain identification system and extensive and growing collection of bacteria, viral and fungal strains with Elanco’s expertise in animal health to bring new solutions to the marketplace, the release said.

“AgBiome’s vast strain library and unique knowledge and methods for strain identification and development are particularly interesting to Elanco,” said Aaron Schacht, executive vice president of Innovation, Regulatory and Business Development at Elanco. “Identifying and developing new products and tools to help manage the animal’s microbiome, control infections, and reduce gut inflammation, while decreasing the need for medically important antibiotics is a top priority for Elanco.”

Elanco is committed to bringing greater clarity and collaboration to issues around antibiotic stewardship, the release said. In 2015, the company released an aggressive, multi-faceted 8-point Antibiotic Stewardship Plan that includes 1) increasing responsible antibiotic use; 2) reducing the need for shared-class antibiotics; and 3) replacing antibiotics with alternatives to help livestock producers treat and prevent animal disease. The plan includes a commitment to deliver antibiotic alternatives, such as vaccines, enzymes and probiotics.